Compare Ascendis Pharma A/S (ASND) vs Dropbox Inc (DBX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Dropbox Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Dropbox Inc trades at $29.17 (market cap $6.81B). The key difference: Ascendis Pharma A/S is far larger — about 2.6× Dropbox Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Dropbox Inc nearer its low. Which is the better fit depends on your goals.
| ASND | DBX | |
|---|---|---|
Market Cap | $17.74B | $6.81B |
Sector | Health | Technology |
52-Week High | $277.18 | $32.17 |
52-Week Low | $163.32 | $22.06 |
Enterprise Value | $18.11B | $9.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
DBX trades at $29.19, down 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported revenue of $2.52 billion in 2025 with a net income margin of 20.16%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights a $900 million stock repurchase program and CEO transition plans announced in May 2026.
Outlook is mixed with strong profitability and consistent earnings beats offset by negative shareholder equity and high debt levels. The consensus price target of $30 suggests modest upside, but investors face risks from leadership changes and competitive pressures in cloud storage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
